Complications Flashcards

1
Q

Risk factors for AIH recurrence following LT

A
  1. Increasing time post-tx
  2. DC of steroids
  3. Poorly controlled AIH pre-txp
  4. Concomitant autoimmune diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Islet Cell Txp Complications

A
  1. Bleeding
  2. PVT (2/2 txp procedure via protal vein; consider ppx)
  3. Pain
  4. Mild AST/ALT elevations (engraftment in liver; should resolve)
  5. Sensitization (risk inc with # of donors)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Panc Txp vs Islet Cell Txp

  • Insulin Independence
  • Adverse events
  • Duration hospitalization
A
  • Insulin Independence: Panc wins
  • Adverse events: Islet cell wins (panc has more thrombosis, relap, CMV reactivation)
  • Duration hospitalization: Islet cell wins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Risk factors for FSGS recurrence

A
  • 1st txp failed dt recurrence
  • Rapid progression to ESRD
  • Young age at time of diagnosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Indications for kidney bx per KDIGO

A

9.1: We recommend kidney allograft biopsy when there is a persistent, unexplained increase in serum creatinine. (1C)
9.2: We suggest kidney allograft biopsy when serum creatinine has not returned to baseline after treatment of acute rejection. (2D)
9.3: We suggest kidney allograft biopsy every 7–10 days during delayed function. (2C)
9.4: We suggest kidney allograft biopsy if expected kidney function is not achieved within the first 1–2 months after transplantation. (2D)
9.5: We suggest kidney allograft biopsy when there is:
• new onset of proteinuria (2C);
• unexplained proteinuria ≥3.0 g/g creatinine or ≥3.0 g per 24 hours. (2C)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

KDIGO recs for FSGS recurrence screening

A
Screen for proteinuria
• daily for 1 week (2D);
• weekly for 4 weeks (2D);
• every 3 months, for the first year (2D);
• every year, thereafter. (2D)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

KDIGO recs for IgA/MPGN/anti-GBM/ANCA recurrence screening

A

Screen for proteinuria, microhematuria:
• once in the first month to determine a baseline (2D);
• every 3 months during the first year (2D);
• annually, thereafter. (2D)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Treatment of recurrent FSGS

A

We suggest plasma exchange if a biopsy shows minimal change disease or FSGS
in those with primary FSGS as their primary kidney disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment of recurrent anti-GBM/ANCA

A

We suggest high-dose corticosteroids and cyclophosphamide in patients with recurrent ANCA-associated vasculitis or anti-GBM disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cause of pre-kidney txp secondary hyperparathyroidism? Implications on phos, Ca, Vit D?

A

Renal function declines –> reduction in phosphate reabsorption in the nephrons via FGF23 –> PTH increases to maintain phosphate balance

Phos: Elevated
Ca: Dec (dt inc PTH, bone resorption)
Vit D: Dec (dt dec 1a hydroxylase in kidney to conver to active vit D)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Treatment of secondary hyperparathyroidism post-txp

A
  • Calcimimetics if elevated PTH
  • Vit D or calcitriol pending 25HD level
  • Surgical parathyroidectomy PRN
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Monitoring of secondary hyperparathyroidism post-txp

A

Immediately post-txp: Monitor Ca and Phos at least weekly

Then, monitor PTH, Ca, Phos with frequency depending on abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Requirements to be within Milan Critera

A
- Solitary tumor <5 CM 
OR
- Up to 3 tumor nodules (each < 3CM)
AND
No extra hepatic or vascular invasion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which type of pancreas txp has the highest risk of rejection?

A

PTA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Islet allograft survival: donor and recipient factors

A
  • Induction
  • Calcineurin inhibitor maintenance
  • > 500 000 islet equivalents infused
  • Recipient age >35
  • Donor BMI >30 with A1c <6.5%
  • <43 units/day pretransplant insulin requirements
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Recommended volume for islet cell txp

A

Preferred: >7k IE/kg from single donor
Acceptable: >5k IE/kg

17
Q

Anti-inflammatory medications that improve islet cell engraftment & insulin independence

A

Block inflammatory reaction:

  1. Anti-TNF (Etanercept)
  2. IL-1 receptor antagonist (Anakinra)
18
Q

Non-Anti-inflammatory medications that improve islet cell engraftment and/or insulin independence

A
  1. Heparin (UFH or LMWH to target aPTT): counteract thromobogenic effects of islets
  2. Insulin to target normoglycemia: anti-inflammatory properties
  3. GLP-1 Receptor Agonists: augment insulin production by islets
19
Q

Risk for bacteremia post-intestinal txp

A
  • Liver graft
  • Pre-op bili >5
  • Pediatrics
    Note: G+ > G- > fungal
20
Q

Foods that cause dumping syndrome

A
  • Insoluble cellulose

- Simple carbohydrates

21
Q

Risk factors for PTLD post-intestinal txp

A
  • ITx
  • Primary EBV infxn
  • Depleting induction
  • Young recipient age
22
Q

Risk factors for poor outcomes post-heart txp (donor & recip & surgical)

A

Donor

  • Older age (>50)
  • Gender mismatch
  • Size mismatch
  • LV thickness >1.4 cm

Recipient

  • Pre-txp amio use
  • The usual: older age, DM, HTN, obesity, vascular dz, frailty

Surgical
- Ischemic tima (ideal <4 hr; max 6 hr)

23
Q

Ideal vasoactives post-heart txp

A
  1. Something with minimal vasodilation (likely vasoplegic after OR) - NOT isoproterenol
  2. Chronotropy - Anything with beta/milrinone
  3. Increased contractility (stunted from cold time) - Anything with beta/milrinone
  4. Decreased arrhythmia risk - NOT isoproterenol, epi
24
Q

What decrease in FEV1 is considered significant for lung dysfunction?

A

10%+